We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Reagent Shortage Drives IVD Segment in India

By LabMedica International staff writers
Posted on 25 Aug 2010
Laboratory chains prepare to meet the growing medical needs of the 1.18 billion people living in India. However, the strong growth is producing a shortage of reagents on the market.

As the gross domestic product (GDP) growth rate in India nears 9%, diagnostic manufacturers are preparing to collect their share of the in vitro (IVD) diagnostics market, which, according to healthcare market research publisher Kalorama Information (New York, NY, USA), is expected to enjoy a 15% growth rate through 2014.

Kalorama's report has market projections, pricing comparisons, and profiles of major competitors in the industry. It covers routine chemistry, urine chemistry, hematology, coagulation, cytometry, immunochemistry, rapid testing, blood screening, and molecular testing.

According to Kalorama Information, companies such as), Dr. Lal Path Labs (Gurgaon, India), SRL Ranbaxy (Gurgaon, India), and Quest (Gurgaon, India) are building new laboratories, and frequently engage in partnerships with the public sector. This immense cycle of growth is leading to a shortage in the availability of reagents, as private and public sectors compete for supplies from a growing reagent rental program.

"It's not surprising to see a shortage of reagents in the market,” noted Bruce Carlson, publisher of Kalorama Information. "With the considerable growth in India, there is likely to be a shortage of some medical supplies at various times.”

Metropolitan growth in India has encouraged India's rural citizens to relocate new urban centers, increasing prosperity, insurance availability, and the number of individuals willing to pay for healthcare. The Kalorama report also notes government activity, which promotes medical tourism thus attracting foreign patients interested in paying less for similar healthcare services offered in the west.

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Related Links:

Kalorama Information
Dr. Lal Path Labs
SRL Ranbaxy
Quest Diagnostics India




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Automated Immunoassay Analyzer
SuperFlex™
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA

Latest Industry News

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
25 Aug 2010  |   Industry

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
25 Aug 2010  |   Industry

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
25 Aug 2010  |   Industry